CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD) CEO Thomas P. Mathers sold 1,502 shares of CoLucid Pharmaceuticals stock in a transaction that occurred on Wednesday, October 5th. The shares were sold at an average price of $37.08, for a total transaction of $55,694.16. Following the sale, the chief executive officer now owns 248,169 shares of the company’s stock, valued at $9,202,106.52. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD) traded up 1.034% during trading on Friday, hitting $36.635. 73,217 shares of the stock traded hands. The stock’s market cap is $561.76 million. The firm’s 50-day moving average is $22.84 and its 200-day moving average is $11.23. CoLucid Pharmaceuticals Inc. has a 12 month low of $3.60 and a 12 month high of $39.27.

CoLucid Pharmaceuticals (NASDAQ:CLCD) last announced its quarterly earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($1.06) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by $0.22. On average, analysts forecast that CoLucid Pharmaceuticals Inc. will post ($3.91) EPS for the current year.

Insider Buying and Selling by Quarter for CoLucid Pharmaceuticals (NASDAQ:CLCD)

CLCD has been the subject of several research reports. Zacks Investment Research upgraded shares of CoLucid Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 17th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $21.00 target price on shares of CoLucid Pharmaceuticals in a report on Thursday, September 1st. Ladenburg Thalmann lifted their target price on shares of CoLucid Pharmaceuticals from $23.00 to $52.00 and gave the company a “buy” rating in a report on Tuesday, September 6th. Finally, Stifel Nicolaus lifted their target price on shares of CoLucid Pharmaceuticals from $27.00 to $30.00 and gave the company a “buy” rating in a report on Monday, September 19th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $33.05.

A number of institutional investors have recently made changes to their positions in the stock. FMR LLC purchased a new stake in CoLucid Pharmaceuticals during the second quarter valued at $554,000. Vanguard Group Inc. increased its stake in CoLucid Pharmaceuticals by 1.2% in the second quarter. Vanguard Group Inc. now owns 76,242 shares of the biopharmaceutical company’s stock valued at $623,000 after buying an additional 900 shares during the last quarter. Finally, Societe Generale purchased a new stake in CoLucid Pharmaceuticals during the second quarter valued at $464,000. Institutional investors own 30.47% of the company’s stock.

CoLucid Pharmaceuticals Company Profile

CoLucid Pharmaceuticals, Inc is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies.

5 Day Chart for NASDAQ:CLCD

Receive News & Stock Ratings for CoLucid Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CoLucid Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.